This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2018 Nov;8(11):1491.

doi: 10.1158/2159-8290.CD-18-1115.

Correction: Phase I Dose-Escalation Study of Taselisib, an Oral PI3KInhibitor, in Patients with Advanced Solid Tumors

No authors listed

PMID: 30385526
DOI: 10.1158/2159-8290.CD-18-1115

Published Erratum

Correction: Phase I Dose-Escalation Study of Taselisib, an Oral PI3KInhibitor, in Patients with Advanced Solid Tumors

No authors listed. Cancer Discov. 2018 Nov.

. 2018 Nov;8(11):1491.

doi: 10.1158/2159-8290.CD-18-1115.

PMID: 30385526
DOI: 10.1158/2159-8290.CD-18-1115

No abstract available

PubMed Disclaimer

Erratum for

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Juric D, Krop I, Ramanathan RK, Wilson TR, Ware JA, Sanabria Bohorquez SM, Savage HM, Sampath D, Salphati L, Lin RS, Jin H, Parmar H, Hsu JY, Von Hoff DD, Baselga J. Juric D, et al. Cancer Discov. 2017 Jul;7(7):704-715. doi: 10.1158/2159-8290.CD-16-1080. Epub 2017 Mar 22. Cancer Discov. 2017. PMID: 28331003 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems